BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

NCT00949650 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

345

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Adenocarcinoma

Interventions

DRUG: Pemetrexed
DRUG: BIBW 2992
DRUG: Cisplatin

Sponsor

Boehringer Ingelheim